Displaying items by tag: harbert institute for innovation and entrepreneurship

The monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness, potentially lasting a year or more when used in humans.
In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus.
A local early-stage startup has been approved for low-cost, low-risk, non-invasive procedures for patients with chronic liver disease.
The research is led by an Oregon cancer research institute, in collaboration with two biotech companies and the National Institutes of Health.
Page 2 of 2